Last Updated on November 7, 2024 by The Health Master
Dobustat
The National Pharmaceutical Pricing Authority (NPPA) has once again faced scrutiny over its pricing decisions. This time, the spotlight is on the drug Dobustat 250 mg injection, manufactured by Samarth Life Sciences.
A recent ruling by the Department of Pharmaceuticals (DoP) has upheld the NPPA’s decision to impose a price cap on this essential medication.
The Price Cap Controversy
The controversy began when NPPA, in March 2023, set a ceiling price of Rs. 8.05 per ml for Dobustat.
This price was later revised to Rs. 9.02 per ml. Samarth Life Sciences challenged this decision, arguing that the NPPA had erred in its calculations.
Samarth’s Argument
Samarth contended that the drug is sold in 5 ml vials and, therefore, the price should be calculated per ml rather than per pack.
The company argued that the NPPA’s pricing methodology violated the Drugs (Prices Control) Order (DPCO) of 2013.
NPPA’s Stance
The NPPA defended its decision, stating that the price was determined according to existing rules and aligned with the DPCO’s schedule.
The authority emphasized that the formulation of Dobutamine, listed in Schedule I of DPCO 2013, should be priced on a per ml basis for a 50 mg/ml concentration.
DoP’s Final Verdict
After a thorough review of the arguments presented by both parties, the Department of Pharmaceuticals upheld the NPPA’s decision.
The DoP found that the NPPA had correctly adhered to the DPCO guidelines when determining the ceiling price for Dobutamine injections.
Key Takeaways:
- The NPPA’s decision to impose a price cap on Dobustat 250 mg injection has been upheld.
- Samarth Life Sciences’ challenge to the pricing methodology was dismissed.
- The NPPA’s decision was found to be in compliance with the Drugs (Prices Control) Order (DPCO) 2013.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
Govt upholds ceiling price fixation for Azathioprine 50 mg
Clotrimazole Cream Price Dispute: Govt upholds NPPA’s Ceiling Price
NPPA orders Price Cut on these Cancer Drugs
NPPA revised Ceiling price of 11 scheduled formulations: October 2024
NPPA fixed retail price of 20 formulations: October 2024
Anti dumping probe on Calcium Carbonate
Delhi Court orders Permanent Injunction in a Trademark case
CDSCO to implement stricter regulations for health supplements
Important short notes for Industry
Govt upholds ceiling price fixation for Azathioprine 50 mg
CDSCO Nod granted to Conduct Clinical Trial of Ruxolitinib cream
No provision for separate license for Pharma marketers
Important short notes for Industry
Deadly reactor explosion at Pharma Plant in Andhra Pradesh
Drug recall: Dr Reddy’s recalls Cinacalcet Tablets due to impurity Concerns
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
